Laura Prendergast
Stock Analyst at Stifel
(3.47)
# 942
Out of 5,138 analysts
14
Total ratings
53.85%
Success rate
39.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Initiates: Buy | $15 | $13.01 | +15.30% | 1 | Dec 4, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $12 | $6.02 | +99.34% | 1 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $104.26 | +29.48% | 2 | Nov 17, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Buy | $8 | $2.56 | +212.50% | 2 | Oct 16, 2025 | |
| RVMD Revolution Medicines | Reinstates: Buy | $85 | $120.28 | -29.33% | 3 | Oct 16, 2025 | |
| ERAS Erasca | Initiates: Buy | $4 | $9.62 | -58.42% | 2 | Oct 16, 2025 | |
| COGT Cogent Biosciences | Initiates: Hold | $16 | $38.94 | -58.91% | 1 | Oct 16, 2025 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.04 | +684.31% | 2 | Aug 14, 2024 |
Tango Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $15
Current: $13.01
Upside: +15.30%
Foghorn Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $12
Current: $6.02
Upside: +99.34%
Nuvalent
Nov 17, 2025
Maintains: Buy
Price Target: $115 → $135
Current: $104.26
Upside: +29.48%
Black Diamond Therapeutics
Oct 16, 2025
Reinstates: Buy
Price Target: $8
Current: $2.56
Upside: +212.50%
Revolution Medicines
Oct 16, 2025
Reinstates: Buy
Price Target: $85
Current: $120.28
Upside: -29.33%
Erasca
Oct 16, 2025
Initiates: Buy
Price Target: $4
Current: $9.62
Upside: -58.42%
Cogent Biosciences
Oct 16, 2025
Initiates: Hold
Price Target: $16
Current: $38.94
Upside: -58.91%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.04
Upside: +684.31%